Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 1:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 38 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Pivotal Response Treatment Clear all
Completed Not applicable Interventional

Evaluating Parent Delivered Interventions for Children With Autism

NCT01882153
View directory record Official record
Conditions
Autistic Disorder, Developmental Disabilities
Interventions
Pivotal Response Training (PRT), PACE Therapy, PACE and PRT Hybrid
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
18 Months to 17 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2022
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jul 13, 2023 · Synced Sep 23, 2026, 1:12 PM EDT
Not listed Not applicable Interventional

PRT for Adolescents With High Functioning Autism

NCT05987761
View directory record Official record
Conditions
Autism, Autism Spectrum Disorder High-Functioning, Developmental Disability, Child Development, Behavior, Child, Behavior, Social
Interventions
PRT for Adolescents
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
11 Years to 14 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Mar 27, 2024 · Synced Sep 23, 2026, 1:12 PM EDT
Completed Not applicable Interventional

Pivotal Response Treatment for Individuals With Intellectual Disabilities

NCT01988623
View directory record Official record
Conditions
Intellectual Disabilities, Speech Delay, Language Disorder
Interventions
Pivotal Response Treatment (PRT)
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
2 Years to 17 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jan 11, 2021 · Synced Sep 23, 2026, 1:12 PM EDT
Completed Not applicable Interventional

Pivotal Response Treatment for Children With Autism Spectrum Disorders

NCT01908686
View directory record Official record
Conditions
Autism Spectrum Disorders
Interventions
Pivotal Response Training
Behavioral
Lead sponsor
Yale University
Other
Eligibility
4 Years to 35 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 13, 2020 · Synced Sep 23, 2026, 1:12 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Tracking Intervention Effects With Eye Tracking

NCT02856061
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
Pivotal Response Treatment
Behavioral
Lead sponsor
Yale University
Other
Eligibility
4 Years to 7 Years
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 8, 2020 · Synced Sep 23, 2026, 1:12 PM EDT
Completed Phase 3 Interventional

Efficacy & Safety of Resatorvid in Adults With Severe Sepsis

NCT00143611
View directory record Official record
Conditions
Sepsis
Interventions
Resatorvid, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
277 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
49
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2012 · Synced Sep 23, 2026, 1:12 PM EDT
Completed Not applicable Interventional

Improving Access to Pivotal Response Treatment (PRT) Via Telehealth Parent Training

NCT04042337
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
Pivotal Response Treatment
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
2 Years to 5 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Nov 16, 2025 · Synced Sep 23, 2026, 1:12 PM EDT
Terminated No phase listed Observational

Long-term Follow-up Durability (Efficacy) Study of EN3835 for the Treatment of AC of the Shoulder (Frozen Shoulder)

NCT04680156
View directory record Official record
Conditions
Adhesive Capsulitis, Frozen Shoulder
Interventions
Previously treated with EN3835 up to 1.74 mg or Placebo in EN3835-210 or the pivotal phase 3 studies
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
30
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 25 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2022 · Synced Sep 23, 2026, 1:12 PM EDT
Completed Not applicable Interventional

Pivotal Response Treatment (PRT) Telemedicine

NCT03045263
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
Pivotal Response Treatment
Behavioral
Lead sponsor
Yale University
Other
Eligibility
3 Years to 6 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 25, 2020 · Synced Sep 23, 2026, 1:12 PM EDT
Not listed Phase 2 Interventional

Alpelisib, Fulvestrant and Dapagliflozin for the Treatment of HR+, HER2 -, PIK3CA Mutant Metastatic Breast Cancer

NCT05025735
View directory record Official record
Conditions
Metastatic Breast Cancer, HER2-negative Breast Cancer
Interventions
Dapagliflozin 10Mg Tab
Drug
Lead sponsor
Saint Luke's Health System
Other
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 18, 2021 · Synced Sep 23, 2026, 1:12 PM EDT
Active, not recruiting Not applicable Interventional

Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Cutaneous Squamous Cell Carcinoma

NCT05323253
View directory record Official record
Conditions
Recurrent Squamous Cell Carcinoma
Interventions
DaRT seeds
Device
Lead sponsor
Alpha Tau Medical LTD.
Industry
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
23
States / cities
Gilbert, Arizona • Phoenix, Arizona • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Sep 23, 2026, 1:12 PM EDT
Completed Phase 3 Interventional Results available

A Study to Assess Whether Etrolizumab is a Safe and Efficacious Treatment for Participants With Moderately to Severely Active Crohn's Disease

NCT02394028
View directory record Official record
Conditions
Crohn Disease
Interventions
Etrolizumab, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,035 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
62
States / cities
Arcadia, California • La Jolla, California • Long Beach, California + 53 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2022 · Synced Sep 23, 2026, 1:12 PM EDT
Completed Phase 3 Interventional Results available

Outpatient Study to Evaluate Safety and Effectiveness of the Low Glucose Suspend Feature

NCT01497938
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Medtronic MMT-754 Veo Insulin pump testing Low Glucose Suspend (LGS) feature, Medtronic (NO LGS FEATURE ) using Paradigm® Revel™2.0 Pump
Device
Lead sponsor
Medtronic MiniMed, Inc.
Industry
Eligibility
16 Years to 70 Years
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
17
States / cities
Little Rock, Arkansas • Escondido, California • San Mateo, California + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2014 · Synced Sep 23, 2026, 1:12 PM EDT
Active, not recruiting Phase 2 Interventional

Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow

NCT03363373
View directory record Official record
Conditions
Neuroblastoma
Interventions
GM-CSF + Naxitamab
Biological
Lead sponsor
Y-mAbs Therapeutics
Industry
Eligibility
1 Year and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
2
States / cities
Indianapolis, Indiana • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 23, 2026, 1:12 PM EDT
Completed Phase 1Phase 2 Interventional

Senicapoc and Dehydrated Stomatocytosis

NCT04372498
View directory record Official record
Conditions
Dehydrated Hereditary Stomatocytosis
Interventions
Senicapoc (synonyms: ICA-17043; 2,2-bis-(4-fluorophenyl)-2-phenylacetamide)
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
21 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 21, 2024 · Synced Sep 23, 2026, 1:12 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Online Pivotal Response Treatment Training in Autism Spectrum Disorder

NCT06523387
View directory record Official record
Conditions
Autism Spectrum Disorder, Autism
Interventions
Pivotal Response Treatment Online (PRT-O) Course
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
2 Years to 5 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Sep 23, 2026, 1:12 PM EDT
Recruiting Phase 3 Interventional

A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-004)

NCT07705555
View directory record Official record
Conditions
Diabetic Retinopathy, Macular Edema
Interventions
MK-8748, Aflibercept
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
960 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
8
States / cities
Glendale, California • Denver, Colorado • Tampa, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Sep 23, 2026, 1:12 PM EDT
Completed Not applicable Interventional Results available

Pivotal Response Group Treatment for Parents of Young Children With Autism

NCT01881750
View directory record Official record
Conditions
Autistic Disorder
Interventions
Pivotal Response Training (PRT), Parent Education Group (PEG)
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
2 Years to 6 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 15, 2019 · Synced Sep 23, 2026, 1:12 PM EDT
Completed Phase 1 Interventional Results available

Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors

NCT02723864
View directory record Official record
Conditions
Neoplasms
Interventions
Veliparib + VX-970 + Cisplatin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
3
States / cities
Bethesda, Maryland • Boston, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 7, 2022 · Synced Sep 23, 2026, 1:12 PM EDT
Completed Not applicable Interventional

EMPOWER AUD Pivotal Trial

NCT05948605
View directory record Official record
Conditions
Alcoholism, Alcohol Abuse, Alcohol Use Disorder
Interventions
Empower Neuromodulation System
Device
Lead sponsor
Theranova, L.L.C.
Industry
Eligibility
21 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
San Francisco, California • New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 10, 2025 · Synced Sep 23, 2026, 1:12 PM EDT
Completed Not applicable Interventional

Pivotal Response Treatment for Infants At-Risk for Autism Spectrum Disorder

NCT01691066
View directory record Official record
Conditions
Autism Spectrum Disorders
Interventions
Infant Toddler Years PRT
Behavioral
Lead sponsor
Yale University
Other
Eligibility
12 Months to 15 Months
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 25, 2020 · Synced Sep 23, 2026, 1:12 PM EDT
Completed Not applicable Interventional

Promoting Transactional Supports to Optimize Social Communication Outcomes for Infants and Their Families

NCT03307057
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
Social Communication Growth Charts (SCGC), Parent-Implemented (P-I) Condition, Clinician-Implemented (C-I) Condition, Usual Care
Behavioral
Lead sponsor
Emory University
Other
Eligibility
6 Months to 6 Months
Enrollment
269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Sep 23, 2026, 1:12 PM EDT
Recruiting Not applicable Interventional

Trial of an Online Spanish Pivotal Response Treatment Training in Autism Spectrum Disorder

NCT06690255
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
Pivotal Response Treatment
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
2 Years to 5 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jun 21, 2026 · Synced Sep 23, 2026, 1:12 PM EDT
Completed Not applicable Interventional

Pivotal Response Treatment Package for Young Children With Autism

NCT02037022
View directory record Official record
Conditions
Autism Spectrum Disorder (ASD), Autism
Interventions
Pivotal Response Treatment Package (PRT-P)
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
2 Years to 5 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 24, 2020 · Synced Sep 23, 2026, 1:12 PM EDT